Fassett Michael J, Hernandez Lopez Adrian L
Department of Obstetrics and Gynecology, Kaiser Permanente Southern California, West Los Angeles Medical Center, 6041 Cadillac Ave 3rd Floor, Los Angeles, CA 90034, United States of America.
Department of Obstetrics and Gynecology, Kaiser Permanente Southern California, Los Angeles Medical Center, 4900 Sunset Blvd 5th Floor, Los Angeles, CA 90027, United States of America.
Case Rep Womens Health. 2021 Feb 11;30:e00294. doi: 10.1016/j.crwh.2021.e00294. eCollection 2021 Apr.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease caused by mutations in hematopoietic stem cells leading to pancytopenia and a predisposition for thromboembolic events. In pregnancy, these manifestations can be amplified, leading to increased neonatal and maternal morbidity and mortality. Although data are limited, eculizumab has emerged as a potential treatment of PNH in pregnancy. This report describes a case of a woman with PNH successfully treated with eculizumab during two pregnancies. Although during both pregnancies she experienced breakthrough hemolysis requiring intermittent blood transfusions, she had no thromboembolic events and had term vaginal births. Granted more research is needed, eculizumab may be an acceptable therapy for PNH in pregnancy.
阵发性睡眠性血红蛋白尿(PNH)是一种罕见疾病,由造血干细胞突变引起,导致全血细胞减少,并易发生血栓栓塞事件。在妊娠期间,这些表现可能会加重,导致新生儿和孕产妇发病率及死亡率增加。尽管数据有限,但依库珠单抗已成为妊娠期间PNH的一种潜在治疗方法。本报告描述了一名患有PNH的女性在两次妊娠期间成功接受依库珠单抗治疗的病例。尽管在两次妊娠期间她都经历了突破性溶血,需要间歇性输血,但她没有发生血栓栓塞事件,并且足月阴道分娩。鉴于需要更多的研究,依库珠单抗可能是妊娠期间PNH的一种可接受的治疗方法。